UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)

UT 西南转化医学中心 (UL1/KL2/TL1)

• 批准号: 8743348
• 负责人: ROBERT Daniel TOTO
• 金额: $ 531.77万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-26 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8743348
• 关键词: Applications Grants; Area; Award; Bioinformatics; Biometry; Clinical; Clinical Research; Communities; Community Health; Detection; Devices; Diagnosis; Disease; Elements; Environment; Funding; Genomics; Goals; Grant; Health; Health Personnel; Health Sciences; Home environment; Hospitals; Human; Instruction; Intervention; Knowledge; Leadership; Malignant Neoplasms; Medical; Movement; Outcomes Research; Patient-Focused Outcomes; Pharmaceutical Preparations; Population Research; Population Sciences; Positioning Attribute; Prevention; Principal Investigator; Proteomics; Public Health; Recruitment Activity; Research; Research Infrastructure; Research Institute; Research Personnel; Resources; Scientist; Systems Biology; Texas; Training and Education; Translating; Translational Research; Translations; Validation; Vision; Work; biomedical informatics; clinical practice; commercialization; design; effective therapy; falls; improved; innovation; metabolomics; novel diagnostics; novel therapeutics; programs; stem cell biology; translational medicine

Program Director/Principal Investigator (Last, First, Middle): T o t O , R o b e r t D . PROJECT SUMMARY (See instmctions): The CTSA has had a major impact on the clinical and translational research (CTR) environment at UT Southwestern. Many new and highly successful programs in education and training, pilot grant awards, biomedical informatics (BMI), biostatistics, population research, community health sciences, and patient- centered outcomes research have been established. Concurrently, the CTSA stimulated UT Southwestern to invest heavily in CTR infrastructure by recruiting new clinical and translational researchers into leadership positions of major clinical departments, by creating a new research institute that focuses on stem cell biology and cancer and by greatly enhancing genomics, metabolomics, proteomics, bioinformatics, and systems biology. Two new, state-of-the art hospitals are under construction, to open in fall 2014, and they incorporate design elements that will support CTR. Our vision is to accelerate translation of new discoveries into clinical practice (T0-T4) by leveraging our scientific strengths. We will integrate and centralize our resources to work in an encouraging and collaborative research environment. Our three Specific Aims are to: 1) Enhance our Research Environment to Accelerate Translation of Discovery into Practice. We formed the Center for Translational Medicine (Center), directed by the CTSA PI, to serve as the new integrated home for our CTSA. The Center will coordinate and expand the clinical research enterprise while it educates clinical and translational researchers at every level. 2) Leverage Existinq and New Resources to Build on Four Innovative Programs in Translation including: a) Target Identification and Validation; b) Discovery in Humans; c) Intervention in Humans and d) Population Science and Community Engagement. 3) Share Knowledge and Discoverv. and Contribute to the Leadership of the National Consortium. We will share gains that are made in our programs in educational and translational research programs with the Texas Regional CTSA consortium and National CTSA Consortium. We will contribute to leadership in areas of translation including T0-T4 research, and discovery and commercialization of new drugs and devices. Our vision for accelerating CTR is well aligned with the new NCATS initiatives and takes full advantage of gains made in the previous funding. We will establish new and improved programs that will enable investigators to discover, translate and disseminate new knowledge that will improve the prevention, detection, diagnosis, and effective treatment of disease. RELEVANCE (See instructions): Improving the health of our nation requires a concerted effort by medical scientists, health care providers and public health policymakers. This grant application will provide the crucial infrastructure necessary for medical scientists to discover and apply new diagnostics and therapeutics for the detection, prevention, detection, diagnosis and effective treatment of disease. The goal is to accelerate the movement of these new discoveries into clinical practice to improve our nation's health in a safe and effective manner.

项目总监/首席研究员（最后、第一、中间）：Tot O , Robert D . 项目摘要（参见说明）： CTSA 对 UT 的临床和转化研究 (CTR) 环境产生了重大影响 西南。许多新的、非常成功的教育和培训项目、试点补助金、 生物医学信息学 (BMI)、生物统计学、人口研究、社区健康科学和患者 已建立以成果为中心的研究。与此同时，CTSA 刺激 UT 西南大学 通过招募新的临床和转化研究人员担任领导层，大力投资 CTR 基础设施 通过创建一个专注于干细胞生物学的新研究所，占据主要临床部门的职位 和癌症，并通过极大地增强基因组学、代谢组学、蛋白质组学、生物信息学和系统 生物学。两座最先进的新医院正在建设中，将于 2014 年秋季开业， 纳入支持点击率的设计元素。我们的愿景是加速新发现的转化 利用我们的科学优势进入临床实践（T0-T4）。我们将整合并集中我们的 在令人鼓舞和协作的研究环境中工作的资源。我们的三个具体目标是 目的： 1) 改善我们的研究环境，加速将发现转化为实践。我们 成立了转化医学中心（中心），由 CTSA PI 指导，作为新的 我们 CTSA 的综合住宅。该中心将协调和扩大临床研究事业 同时它还对各个级别的临床和转化研究人员进行教育。 2) 利用现有的和新的 构建四个翻译创新计划的资源，包括：a) 目标识别和 验证; b) 在人类中的发现； c) 对人类的干预 d) 人口科学和社区 订婚。 3) 分享知识和发现。并为国家的领导作出贡献 财团。我们将分享我们在教育和转化研究项目中取得的成果 与德克萨斯州地区 CTSA 联盟和国家 CTSA 联盟合作的项目。我们将致力于 在翻译领域处于领先地位，包括 T0-T4 研究以及新成果的发现和商业化 药物和设备。 我们加快点击率的愿景与新的 NCATS 举措非常一致，并充分利用 充分利用前期融资所取得的收益。我们将制定新的和改进的计划， 使调查人员能够发现、转化和传播新知识，从而改善预防、 疾病的检测、诊断和有效治疗。 相关性（参见说明）： 提高我国人民的健康水平需要医学科学家、卫生保健人员和广大人民群众的共同努力。 公共卫生政策制定者。该赠款申请将提供必要的关键基础设施 医学科学家发现并应用新的诊断和治疗方法来检测、预防、 疾病的检测、诊断和有效治疗。目标是加速这些运动 将新发现应用于临床实践，以安全有效的方式改善我们国家的健康。